Why the study?
Is there a disparity in real-world eligibility for the initiation of ticagrelor versus prasugrel in patients with acute coronary syndrome?
Is there a disparity in real-world eligibility for the initiation of ticagrelor versus prasugrel in patients with acute coronary syndrome?
Real-world eligibility for prasugrel is substantially lower than for ticagrelor in ACS patients, highlighting a disparity between clinical feasibility and current guideline recommendations.
Answers are grounded in this paper and cite their sources.
Lower prasugrel eligibility versus ticagrelor in ACS warrants clinical caution; leaves open need for prospective validation before guideline shifts.
<0.0001) per PRECISE-DAPT (Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy) score. Conclusions In real life, eligibility for prasugrel in patients requiring dual antiplatelet therapy is considerably lower than for ticagrelor, even in a cohort with high rates of coronary angiography and percutaneous coronary interventions. The recommended use of prasugrel over ticagrelor in current acute coronary syndrome guidelines contrasts with our observations of a substantial disparity on the eligibility. This important aspect has not received appropriate attention yet. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT05774431.
No takes yet. Share an insight, caveat, or question.
Yı́ldı́rı́m et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: